Noom Med review: is it worth it?
Noom Med pairs Noom psychology-based coaching with clinician-prescribed GLP-1.
Worth it if you want coaching bundled with GLP-1 medication
Noom Med stands out by wrapping a clinician-prescribed medication (a compounded or brand-name GLP-1, a tirzepatide dual agonist, or oral metformin) inside Noom's well-known cognitive-behavioral coaching app, which the company's own data associates with better adherence and more weight loss among heavier app users. The medications themselves carry the strongest clinical evidence; Noom adds the habit-change layer. The catch is that lower-priced tiers rely on compounded semaglutide that the FDA does not review for safety, quality, or efficacy, and recurring costs add up. Whether it's right for you depends on your budget, your eligibility, and whether you specifically want an FDA-approved drug. Discuss the options with the prescribing clinician.
Check PriceFrom $149/mo
Pros
- ✓Bundles a clinician-prescribed medication (compounded or brand-name GLP-1, tirzepatide, or metformin) with one of the most-studied behavior-change apps, addressing both biology and habits in one subscription
- ✓Multiple tiers and price points, from a roughly $99/month metformin pill plan to microdose and full-dose compounded GLP-1 options, plus a brand-name telehealth route for FDA-approved drugs
- ✓The medications it prescribes have strong peer-reviewed evidence (STEP 1: about 15% mean weight loss with full-dose semaglutide; SURMOUNT-1: roughly 16% to 22.5% with tirzepatide)
- ✓Includes home delivery, 1:1 and group coaching, and ongoing clinician check-ins, reducing the hassle of separately sourcing a telehealth provider and a pharmacy
- ✓Plans are generally FSA/HSA-eligible, and Noom's own observational data associates heavier app engagement with better medication adherence and more weight loss
Cons
- ✕Lower-priced plans rely on compounded semaglutide and GLP-1s that the FDA does not review for safety, quality, or efficacy, unlike brand-name Ozempic, Wegovy, Mounjaro, or Zepbound
- ✕The FDA has documented dosing errors of 5 to 20 times the intended dose with compounded injectable semaglutide, some causing hospitalization, so self-administration demands real care
- ✕Recurring costs (about $99-$299/month for bundled plans, plus the drug cost if buying brand-name separately) add up and are rarely covered by insurance
- ✕The Microdose plan caps medication below standard maintenance doses, so weight-loss results may fall short of the full-dose clinical-trial figures often cited in marketing
- ✕Quarterly billing and auto-renewal can make canceling or pausing harder than a true month-to-month plan, and weight regain is common after stopping GLP-1 medication
How it works
Noom Med combines two things. First, a licensed clinician reviews an online health assessment and, if appropriate, prescribes a weight-management medication: a compounded or brand-name GLP-1 receptor agonist (semaglutide, the active ingredient in Ozempic/Wegovy), a dual GLP-1/GIP receptor agonist (tirzepatide, the active ingredient in Mounjaro/Zepbound), or an oral option such as metformin. GLP-1 medications mimic a gut hormone that curbs appetite, slows stomach emptying so you feel full longer, and helps regulate blood sugar; tirzepatide adds a second incretin pathway (GIP). Metformin works differently, mainly by reducing the liver's glucose output and improving insulin sensitivity. Second, the Noom app delivers daily cognitive-behavioral-therapy-style lessons on food psychology, habit formation, and emotional eating, plus 1:1 and group coaching, to support the lifestyle changes that help weight-loss results last.
Active ingredient: Brand-name GLP-1
Effectiveness
The medications Noom prescribes carry strong trial evidence, though that evidence comes from the full-dose, FDA-approved products rather than compounded or microdose versions. In the STEP 1 trial (New England Journal of Medicine, 2021), once-weekly semaglutide 2.4 mg plus lifestyle intervention produced a mean 14.9% body-weight loss at 68 weeks versus 2.4% with placebo, with about 69% of treated participants losing at least 10% of their body weight. In SURMOUNT-1 (New England Journal of Medicine, 2022), tirzepatide produced average weight loss of roughly 16.0% to 22.5% depending on dose. Important caveats: Noom's lower-priced plans use compounded GLP-1s, and its Microdose plan deliberately uses doses below the standard maintenance levels studied in these trials, so individual results may be smaller than the headline trial figures. Noom's own 2026 engagement report (observational, 14,203 GLP-1 program members) found that the most-engaged app users lost about 8.3 lbs more by week 40 and stayed on their medication roughly twice as long (about 2.2x) over the first year compared with the least engaged, but the company itself notes this shows correlation, not proof that the app causes the difference. Individual results vary.
Side effects
The most common GLP-1 and tirzepatide side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, abdominal pain, and reflux, usually worst when starting or increasing the dose and often easing over time. Lower-dose (microdose) regimens are marketed partly to blunt these effects, though that benefit is not established in large trials. Serious but less common risks include pancreatitis, gallbladder problems such as gallstones, kidney injury from dehydration, and, in rodent studies, thyroid C-cell tumors, which is why these drugs carry a boxed warning; a causal link to thyroid cancer in humans has not been established. A specific concern with compounded semaglutide: the FDA has warned of dosing errors in which patients received 5 to 20 times the intended dose from multi-dose vials, with adverse events including severe vomiting, fainting, dehydration, and some hospitalizations. Follow dosing instructions exactly, report severe or persistent abdominal pain promptly, and seek medical care for any serious reaction.
Cost
Starts at $149/mo from Noom Med.
As of 2026, Noom Med medication-included plans (priced after a discounted first month and typically billed quarterly) run roughly: the Weight-Loss Pill (metformin) plan around $99/month, the compounded GLP-1Rx plan around $129/month, the compounded Microdose GLP-1Rx plan around $199/month, and the tirzepatide dual-agonist GLP-1Rx Plus plan around $299/month. A separate telehealth tier (around $99/month after the first month) covers clinician care and the app for brand-name drugs such as Ozempic, Wegovy, Mounjaro, or Zepbound, but the medication itself is billed separately through insurance or cash pay (brand-name GLP-1s can list at roughly $1,000 or more per month without coverage). Plans are generally FSA/HSA-eligible. Insurance rarely covers the bundled program or compounded drugs, so expect this to be a recurring out-of-pocket cost; confirm current pricing on Noom's site before enrolling, as plans and prices change.
Is it worth it?
Noom Med is a credible, convenient way to combine medication with behavior change, and its app is among the best-studied in the weight-loss category. But read the fine print: the cheaper plans rely on compounded semaglutide that is not FDA-approved, injectable dosing requires care, and the medication-included pricing (about $99-$299/month) is an ongoing expense most insurers won't cover. The brand-name telehealth tier gives you FDA-approved drugs like Ozempic, Wegovy, Mounjaro, or Zepbound, but you pay for the medication separately, which can run far higher. This is general information, not medical advice; eligibility and treatment choices should be decided with a licensed clinician.
Frequently asked questions
Is Noom Med legit and safe?
Noom Med is a legitimate telehealth program operated by Noom, with licensed clinicians prescribing weight-management medication alongside its coaching app. It can be used safely when directed by a clinician, but its cheaper plans use compounded semaglutide that the FDA does not review for safety, quality, or efficacy, and the FDA has warned about serious dosing errors with compounded injectables. Like any GLP-1 treatment, it carries side-effect and contraindication risks, so it is not appropriate for everyone.
How much does Noom Med cost in 2026?
As of 2026, Noom Med medication-included plans run about $99/month for the metformin pill plan, about $129/month for the compounded GLP-1Rx plan, about $199/month for the compounded Microdose GLP-1Rx plan, and about $299/month for the tirzepatide GLP-1Rx Plus plan, each after a discounted first month and typically billed quarterly. A separate telehealth tier around $99/month covers clinician care and the app for brand-name drugs, but you pay for that medication separately. Prices change, so confirm current rates on Noom's site.
Does Noom Med prescribe real Ozempic and Zepbound, or compounded versions?
Both, depending on the plan. Noom Med offers brand-name, FDA-approved drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound through a telehealth tier where you pay for the medication separately. It also offers lower-cost compounded semaglutide and tirzepatide in its bundled plans. The compounded versions are not FDA-approved and are not reviewed by the FDA for safety, quality, or efficacy.
How much weight can you lose on Noom Med?
Weight loss depends on the medication, the dose, and the individual. The drugs Noom prescribes have strong trial evidence in their full-dose, FDA-approved forms (about 15% mean body-weight loss with semaglutide in STEP 1 and roughly 16% to 22.5% with tirzepatide in SURMOUNT-1), but Noom's Microdose plan uses lower doses, so real-world results are often smaller. Noom's own observational data links heavier app use to greater weight loss, but does not prove the app causes it. Individual results vary.
Is Noom Med covered by insurance?
Usually not. Insurance rarely covers Noom's bundled medication programs or compounded drugs, so they are typically an out-of-pocket cost. The plans are generally FSA/HSA-eligible. If you use the brand-name telehealth tier, your insurance may cover the drug itself (if your plan covers GLP-1s for weight loss), even though Noom's service fee is billed separately. Check your specific plan.
What is the difference between Noom Med Microdose and the standard GLP-1 plan?
The Microdose GLP-1Rx plan deliberately keeps you at a low, sub-maintenance dose, which is marketed to reduce side effects such as nausea while aiming for steady, tolerable weight loss; that side-effect benefit is not established in large trials. The standard or full-dose GLP-1Rx plan titrates up to a higher maintenance dose over time for potentially greater weight loss, with a higher chance of gastrointestinal side effects. A clinician decides which is appropriate.
What are the side effects of Noom Med's GLP-1 medication?
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal pain, usually worst when starting or increasing the dose and often easing over time. Serious but rarer risks include pancreatitis, gallbladder problems, and kidney injury from dehydration; GLP-1 drugs also carry a boxed warning for thyroid C-cell tumors seen in rodent studies (a human causal link is not established). Report severe or persistent abdominal pain promptly and seek care for any serious reaction.
Can you cancel Noom Med easily?
You can cancel, but medication plans are often billed quarterly with auto-renewal, so timing matters and it may be less flexible than a month-to-month subscription. Check your specific plan's renewal date and cancellation terms in your Noom account, and cancel before the next billing cycle to avoid another charge. If you have trouble, contact Noom support directly and keep a record of your request.
Is Noom Med better than other GLP-1 telehealth programs?
There is no single best program; it depends on your needs. Noom Med's main differentiator is bundling medication with its well-studied behavior-change app and coaching, which its data associates with better adherence. Whether it beats alternatives like Ro, Hims & Hers, or Form Health comes down to price, whether you want FDA-approved versus compounded drugs, available doses, and how much you value the coaching layer. Compare on those factors.
Sources
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — New England Journal of Medicine / PubMed (2021)
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — U.S. Food and Drug Administration (2025)
- FDA Alerts Health Care Providers, Compounders and Patients of Dosing Errors Associated with Compounded Injectable Semaglutide Products — U.S. Food and Drug Administration (MedWatch) (2024)
- Lilly's SURMOUNT-1 Results Published in NEJM Show Tirzepatide Achieved Between 16.0% and 22.5% Weight Loss — Eli Lilly and Company / New England Journal of Medicine (2022)
- The Noom Engagement Report: GLP-1 Patients Who Use Noom the Most Lose the Most Weight — Noom (2026)
- Noom Med Plans & Pricing — Noom (2026)